You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Ontario Steering Committee for Cancer Drugs

The Ontario Steering Committee for Cancer Drugs (OSCCD) was created in 2013 to enhance and support the administration of Ontario's cancer drug programs. The committee advises the Ministry of Health and Long-Term Care's Ontario Public Drug Programs and Cancer Care Ontario's Provincial Drug Reimbursement Programs.

The objective is to provide evidence-informed clinical, health research and health economic guidance to the Executive Officer (EO) of Ontario Public Drug Programs (OPDP) on:

  • provincial cancer drug funding policies and decisions
  • program evaluation and drug-specific studies
  • enhancements to cancer drug programs or initiatives in Ontario

For more information on cancer drug funding and decision-making in Ontario, please see the Public Drug Funding and Administration page or visit one of these sites:

To learn more about how the committee is created and organized, refer to the Terms of Reference.

The OSCCD reviews select cancer drugs for public funding in Ontario. The Executive Officer, Ontario Public Drug Programs, seeks the committee’s advice in making final funding decisions. Drug-specific summaries outlining the committee’s recommendations and reasons are available here.

Please note, cancer drugs reviewed by the pan-Canadian Oncology Drug Review are not subsequently assessed by this committee.

OSCCD Cancer Drug Review Summaries

DRUG NAME INDICATION OSCCD REVIEW DATE FUNDING STATUS REVIEW SUMMARY
aprepitant (Emend ®) Chemotherapy-Induced Nausea and Vomiting Nov. 25, 2013 Approved Antiemetics Summary (PDF)
granisetron (Kytril®) Chemotherapy-Induced Nausea and Vomiting Nov. 25, 2013 Approved Antiemetics Summary (PDF)
ondansetron (Zofran®) Chemotherapy-Induced Nausea and Vomiting Nov. 25, 2013 Approved Antiemetics Summary (PDF)
Bevacizumab* (Avastin ®) Recurrent Giloblastoma Multiforme Dec. 12, 2013 Denied See the Ministry’s website: EO Decisions and CED Recom mendations

*The Ministry’s Committee to Evaluate Drugs, led this review with input from the OSCCD.

For current eligibility criteria for publicly funded cancer drugs, please visit the program-specific page or website:

The OSCCD brings together people with expertise from different disciplines including medical oncology, hematology, pharmacy and health economics. It also has patient representation.

All committee members are selected by the Executive Officer of Ontario Public Drug Programs, in consultation with Cancer Care Ontario.

Committee Members

Dr. Kelvin Chan
Medical Oncologist, Sunnybrook Odette Cancer Centre
Assistant Professor, Department of Medicine, University of Toronto

Dr. Henry Conter
Medical Oncologist Medical Director,
Cancer Health System William Osler Health System

Dr. Amit Oza
Professor of Medicine, University of Toronto
Co-Director, Bras Drug Development Program
Director, Cancer Clinical Research Unit, Princess Margaret Cancer Centre

Dr. Stacey Hubay
Medical Oncologist, Grand River Regional Cancer Centre
Assistant Clinical Professor (Adjunct), Department of Oncology, McMaster University

Dr. Matthew Cheung
Assistant Professor, Department of Medicine, University of Toronto Clinician-Investigator/Clinical Hematologist, Sunnybrook Health Sciences Centre

Dr. Peter Ellis
Associate Professor, Department of Oncology, McMaster University, Medical Oncologist, Juravinski Cancer Centre 

Dr. Katherine Enright
Medical Oncologist Trillium Health Partners, Credit Valley

Dr. Srikala Sridhar
Medical Oncologist, Division of Medical Oncology, Princess Margaret Hospital Assistant Professor, Department of Medicine, University of Toronto

Laura Wilcock
Oncology Pharmacist, Lakeridge Health, Durham Regional Cancer Centre